Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
March 13, 2024 07:30 ET
|
Atsena Therapeutics
Subretinal injection of ATSN-201 was well tolerated in all patients in first cohort with no serious adverse events reported Enrollment is ongoing in first clinical trial utilizing AAV.SPR, the...
Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
January 16, 2024 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
December 04, 2023 07:30 ET
|
Atsena Therapeutics
ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatmentData accepted for presentation at 47th Annual Macula...
Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
November 14, 2023 07:30 ET
|
Atsena Therapeutics
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1 ATSN-101 has demonstrated clinically meaningful improvements in vision at the highest dose...
Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis
August 28, 2023 07:30 ET
|
Atsena Therapeutics
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling male patients ages 6-64 with RS1-associated XLRS ATSN-201 leverages novel spreading...
Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis
May 01, 2023 07:30 ET
|
Atsena Therapeutics
ATSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate safe delivery of RS1 to photoreceptors in the central retina/fovea Initiation of Phase I/II...
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
April 25, 2023 07:30 ET
|
Atsena Therapeutics
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post treatmentData presented at ARVO 2023 DURHAM, N.C.,...
Atsena Therapeutics Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101 to be Presented at ARVO 2023 Annual Meeting
April 11, 2023 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting
February 08, 2023 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
December 07, 2022 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...